Alnylam CEO Says Firm's Cholesterol Rx Target More 'Compelling' Than Partner Tekmira's

John Maraganore made his comments during a conference call held to discuss the firm's first-quarter financial results, which included a sharp rise in losses amid increased operating costs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.